Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets - PubMed (original) (raw)
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets
B C Tel et al. Neuroscience. 2002.
Abstract
Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the direct pathway.The equivalent marked losses of specific [3H]mazindol binding in the striatum of all drug treatment groups confirmed the identical nature of the nigral cell loss produced by MPTP treatment. MPTP-induced destruction of the nigro-striatal pathway markedly increased the level of PPE-A mRNA in the caudate nucleus and putamen and decreased the levels of PPT and PPE-B mRNA relative to normal animals. Repeated treatment with L-DOPA for 30 days produced marked dyskinesia but had no effect on the MPTP-induced increase in PPE-A mRNA in the caudate nucleus and putamen. In contrast, L-DOPA treatment normalised the MPTP-induced decrease in the level of PPT and PPE-B mRNA. Repeated treatment with ropinirole produced little or no dyskinesia but markedly reversed the MPTP-induced elevation in PPE-A mRNA in the caudate nucleus and putamen. However, it had no effect on the decrease in PPT or PPE-B mRNA. Similarly, bromocriptine treatment which induced only mild dyskinesia attenuated the MPTP-induced elevation in PPE-A mRNA in the caudate nucleus and putamen with no effect on reduced striatal PPT or PPE-B mRNA. Neither MPTP treatment nor treatment with L-DOPA, bromocriptine or ropinirole had any effect on adenosine A(2a) receptor mRNA in the striatum. These patterns of alteration in striatal PPE-A and PPT and PPE-B mRNA produced by L-DOPA, bromocriptine and ropinirole show differential involvement of markers of the direct and indirect striatal output pathways related to improvement of locomotor activity and mirror the relative abilities of the drugs to induce dyskinesia.
Similar articles
- Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T. Tamim MK, et al. Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2. Neuropharmacology. 2010. PMID: 19576910 - mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Morin N, Morissette M, Grégoire L, Di Paolo T. Morin N, et al. Curr Neuropharmacol. 2016;14(5):481-93. doi: 10.2174/1570159x14666151201185652. Curr Neuropharmacol. 2016. PMID: 26639458 Free PMC article. Review. - Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments.
Jenner P. Jenner P. J Neurol. 2000 Apr;247 Suppl 2:II43-50. doi: 10.1007/pl00007760. J Neurol. 2000. PMID: 10991665 Review.
Cited by
- Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia.
Hulme H, Fridjonsdottir E, Vallianatou T, Shariatgorji R, Nilsson A, Li Q, Bezard E, Andrén PE. Hulme H, et al. NPJ Parkinsons Dis. 2022 Apr 13;8(1):41. doi: 10.1038/s41531-022-00299-7. NPJ Parkinsons Dis. 2022. PMID: 35418178 Free PMC article. - High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.
Oueslati A, Sgambato-Faure V, Melon C, Kachidian P, Gubellini P, Amri M, Kerkerian-Le Goff L, Salin P. Oueslati A, et al. J Neurosci. 2007 Feb 28;27(9):2377-86. doi: 10.1523/JNEUROSCI.2949-06.2007. J Neurosci. 2007. PMID: 17329435 Free PMC article. - Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA. Westin JE, et al. J Neurosci. 2006 Sep 13;26(37):9448-61. doi: 10.1523/JNEUROSCI.0944-06.2006. J Neurosci. 2006. PMID: 16971529 Free PMC article. - Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.
Gravius A, Dekundy A, Nagel J, Morè L, Pietraszek M, Danysz W. Gravius A, et al. J Neural Transm (Vienna). 2008 Dec;115(12):1609-19. doi: 10.1007/s00702-008-0098-4. Epub 2008 Aug 9. J Neural Transm (Vienna). 2008. PMID: 18690408 - Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Antonini A, et al. Mov Disord. 2016 Apr;31(4):530-7. doi: 10.1002/mds.26528. Epub 2016 Jan 28. Mov Disord. 2016. PMID: 26817533 Free PMC article. Clinical Trial.